全文获取类型
收费全文 | 574篇 |
免费 | 15篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 19篇 |
妇产科学 | 5篇 |
基础医学 | 123篇 |
口腔科学 | 36篇 |
临床医学 | 24篇 |
内科学 | 95篇 |
皮肤病学 | 9篇 |
神经病学 | 28篇 |
特种医学 | 21篇 |
外科学 | 98篇 |
综合类 | 21篇 |
预防医学 | 15篇 |
眼科学 | 4篇 |
药学 | 56篇 |
中国医学 | 10篇 |
肿瘤学 | 27篇 |
出版年
2023年 | 8篇 |
2022年 | 12篇 |
2021年 | 15篇 |
2020年 | 10篇 |
2019年 | 109篇 |
2018年 | 73篇 |
2017年 | 39篇 |
2016年 | 7篇 |
2015年 | 7篇 |
2014年 | 18篇 |
2013年 | 15篇 |
2012年 | 6篇 |
2011年 | 12篇 |
2010年 | 19篇 |
2009年 | 15篇 |
2008年 | 9篇 |
2007年 | 21篇 |
2006年 | 14篇 |
2005年 | 13篇 |
2004年 | 22篇 |
2003年 | 18篇 |
2002年 | 6篇 |
2001年 | 10篇 |
2000年 | 7篇 |
1999年 | 5篇 |
1998年 | 9篇 |
1997年 | 11篇 |
1996年 | 7篇 |
1995年 | 3篇 |
1994年 | 8篇 |
1993年 | 4篇 |
1992年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有592条查询结果,搜索用时 31 毫秒
81.
82.
83.
84.
Sadık Server Soheil Sabet Tolga Sahin Koray Guven Unal Aydın Yaman Tokat Nagihan Inan 《Transplantation proceedings》2019,51(7):2469-2472
ObjectivesAlthough endoscopic management is considered as the first-line treatment for biliary strictures, it may be challenging in living donor liver transplant recipients due to the complex nature of duct-to-duct reconstruction. In this study we present the use of a pigtail drainage catheter as a biliary stent to treat biliary strictures after a living donor liver transplant.MethodsTwenty-seven patients with biliary strictures were treated with our novel technique. In this technique, a pigtail catheter was trimmed into 3 parts (proximal, middle, and distal portions). A suture string was passed through the distal hole of the middle portion, which was then reversed and used as a stent while the proximal portion was used as a pusher. Following balloon dilation of the stenotic segment, the distal, reversed middle, and proximal portions were loaded over the guidewire. After proper placement of the stent, the retractor suture string, pusher, and guidewire were removed. The stent was removed during the third or fourth month of placement through endoscopic retrograde cholangiopancreatography (ERCP) in all patients.ResultsNo significant complications developed during the procedure or follow-up period. Ten patients required re-stenting by ERCP during the same session. The mean follow-up period was 2 years. Cholestase enzymes and bilirubin levels were within normal limits in all patients during follow-up.ConclusionStents derived from drainage catheter facilitate treatment of biliary strictures in patients not eligible for the retrograde approach. This stent is cheap, easy to implement, can be easily removed by ERCP, and re-stenting can be applicable in retrograde if needed. 相似文献
85.
Derya Tilki Felix Preisser Markus Graefen Hartwig Huland Raisa S. Pompe 《European urology》2019,75(6):896-900
The impact of biochemical recurrence (BCR) after radical treatment of prostate cancer on oncological outcomes remains unclear. A new European Association of Urology BCR risk stratification (low and high risk) has been proposed. To validate these risk groups, we retrospectively analyzed data for 1125 post-radical prostatectomy (RP) BCR patients (surgery between 1992 and 2006). Univariable Kaplan-Meier plots and multivariable Cox regression models with time-dependent covariates were used to test the independent predictor status of the risk grouping on metastatic progression (MP) and prostate cancer-specific mortality (PCSM). The 5-yr MP-free and PCSM-free survival rates were significantly higher among patients with low BCR risk compared to their high-risk counterparts. In multivariable analyses, the BCR risk grouping reached independent predictor status for MP (hazard ratio [HR] 3.46; p < 0.001) and PCSM (HR 5.12; p < 0.001). Salvage radiation therapy, especially when delivered at prostate-specific antigen <0.5 ng/ml, was highly protective. Our findings corroborate the validity of this novel BCR risk grouping, which is easily applicable in daily practice and could be valuable in decision-making for salvage therapy and clinical trials.Patient summaryThe European Association of Urology grouping for the risk of biochemical recurrence of prostate cancer after radical prostatectomy was valid when applied in a European study cohort. 相似文献
86.
Annelies Verbiest Inne Renders Stefano Caruso Gabrielle Couchy Sylvie Job Annouschka Laenen Virginie Verkarre Nathalie Rioux-Leclercq Patrick Schöffski Yann Vano Reza-Thierry Elaidi Evelyne Lerut Maarten Albersen Stéphane Oudard Wolf-Hervé Fridman Catherine Sautès-Fridman Laurence Albigès Agnieszka Wozniak Benoit Beuselinck 《Clinical genitourinary cancer》2019,17(5):e981-e994
IntroductionRecent trials have suggested predictive biomarkers in advanced clear-cell renal cell carcinoma (accRCC): International Metastatic RCC Database Consortium (IMDC) good risk or angiogenic gene signature for sunitinib and IMDC intermediate/poor risk for ipilimumab-nivolumab and T-effector cell signature or sarcomatoid dedifferentiation for atezolizumab-bevacizumab. We hypothesized that earlier described molecular subtypes, ccrcc1 to ccrcc4, could provide similar information as a single generic biomarker and molecularly characterize the heterogeneous intermediate-risk group.Patients and MethodsPatients with accRCC treated with systemic therapies were included. We assessed associations between the 5 biomarkers and their impact on progression-free survival (PFS) and response rate (RR) on first-line sunitinib or pazopanib. The cutoff percentage of sarcomatoid dedifferentiation with optimal discriminative value was determined.ResultsIn total, 430 patients were included (163 with molecular data). The molecular ccrcc2 subtype identified tumors with higher angiogenic gene expression across IMDC risk groups: prevalence was high in IMDC good risk and low in IMDC poor risk (P < .001). Molecular subtype, IMDC, and angiogenic gene expression had comparable C-indices to predict PFS and RR (range, 60%-66%). The ccrcc2 subtype and angiogenic gene expression were positive predictors of PFS in IMDC intermediate-risk patients (P = .006; P = .04). Immune signature did not differ between IMDC groups, but was strongly correlated with molecular subtype (P = .8 and P = .0007). A cutoff value of 25% sarcomatoid differentiation discriminated tumors with distinct molecular characteristics and therapeutic sensitivity.ConclusionIn accRCC, molecular subtypes can explain differences in IMDC risk group, expression of angiogenesis and immune response genes, and sarcomatoid dedifferentiation. They can identify molecularly different patient populations within the heterogeneous IMDC intermediate group and select patients for systemic therapies. 相似文献
87.
Allan R. Glanville Geert M. Verleden Jamie L. Todd Christian Benden Fiorella Calabrese Jens Gottlieb Ramsey R. Hachem Deborah Levine Federica Meloni Scott M. Palmer Antonio Roman Masaaki Sato Lianne G. Singer Sofya Tokman Stijn E. Verleden Jan von der Thüsen Robin Vos Gregory Snell 《The Journal of heart and lung transplantation》2019,38(5):483-492
88.
89.
目的探讨野生猕猴桃根黄酮提取物对胃癌MKN-49P细胞增殖作用的影响及机制。方法采用CCK-8比色法、流式细胞术、Western Blot法检测野生猕猴桃根黄酮提取物对胃癌MKN-49P细胞增殖作用的影响。结果野生猕猴桃根黄酮提取物对胃癌MKN-49P细胞增殖有明显的抑制作用,且呈时间-浓度依赖性;其浓度升高,细胞凋亡增加,G1期细胞增加,S、G2/M期细胞减少,抑制周期蛋白CyclinD1表达降低。结论野生猕猴桃根黄酮提取物可抑制胃癌MKN-49P细胞增殖、促进细胞凋亡、阻滞细胞周期于G1期,其主要机制可能与抑制周期蛋白CyclinD1表达降低有关。 相似文献
90.